Skip Navigation

This Article
Right arrow Print PDF (847K)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (65)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Valenzuela, D. M.
Right arrow Articles by Groffen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valenzuela, D. M.
Right arrow Articles by Groffen, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 1986, Vol. 14, No. 2 843-851
© 1986

Articles

Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene

David M. Valenzuela* and John Groffen

Oncogene Science, Inc. 222 Station Plaza North, Mineola, NY 11501, USA

*To whom correspondence should be addressed

Received September 9, 1985. Accepted December 9, 1985.

We have used synthetic oligonucleotides to probe for mutations affecting amino add 12 of the c-K-ras gene in human cell line DNA. Of seven carcinoma cell lines tested,four were found to contain a mutation at this position. In each the nucleotide G was replaced with an A resulting in a Gly to Asp substitution in three cases (cell lines A427, A1165 and A1663) and Gly to Ser in the fourth (A549). Neither of these substitutions have been previously reported in either human tumor or human tumor-derived cell line DNA's. These results indicate that association between mutations involving position 12 of the human c-K-ras oncogene and carcinomas may be stronger than previously recognized.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
B. B. Friday, C. Yu, G. K. Dy, P. D. Smith, L. Wang, S. N. Thibodeau, and A. A. Adjei
BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins
Cancer Res., August 1, 2008; 68(15): 6145 - 6153.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. B. Weidhaas, I. Babar, S. M. Nallur, P. Trang, S. Roush, M. Boehm, E. Gillespie, and F. J. Slack
MicroRNAs as Potential Agents to Alter Resistance to Cytotoxic Anticancer Therapy
Cancer Res., December 1, 2007; 67(23): 11111 - 11116.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Moshnikova, J. Frye, J. W. Shay, J. D. Minna, and A. V. Khokhlatchev
The Growth and Tumor Suppressor NORE1A Is a Cytoskeletal Protein That Suppresses Growth by Inhibition of the ERK Pathway
J. Biol. Chem., March 24, 2006; 281(12): 8143 - 8152.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Schirmer, J. Kennedy, S. Murli, R. Reid, and D. V. Santi
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.
PNAS, March 14, 2006; 103(11): 4234 - 4239.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
M. Refsnes, P. E Schwarze, J. A Holme, and M. Laeg
Fluoride-induced apoptosis in human epithelial lung cells (A549 cells): role of different G protein-linked signal systems
Human and Experimental Toxicology, March 1, 2003; 22(3): 111 - 123.
[Abstract] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. K. Greenberg, J. Hu, S. Basu, J. Hay, J. Reibman, T.-a. Yie, K. M. Tchou-Wong, W. N. Rom, and T. C. Lee
Glucocorticoids Inhibit Lung Cancer Cell Growth through Both the Extracellular Signal-Related Kinase Pathway and Cell Cycle Regulators
Am. J. Respir. Cell Mol. Biol., September 1, 2002; 27(3): 320 - 328.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei, J. N. Davis, C. Erlichman, P. A. Svingen, and S. H. Kaufmann
Comparison of Potential Markers of Farnesyltransferase Inhibition
Clin. Cancer Res., June 1, 2000; 6(6): 2318 - 2325.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
V. A. M. C. Somers, D. A. Leimbach, P. H. M. H. Theunissen, J. J. Murtagh Jr., B. Holloway, A. W. Ambergen, and F. B. J. M. Thunnissen
Validation of the Point-EXACCT method in non-small cell lung carcinomas
Clin. Chem., July 1, 1998; 44(7): 1404 - 1409.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.